180 Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

180 Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$396K	Sell	7,257 -172	-2%	-$9.07K	0.04%	324
2026 Q1	$353K	Buy	7,429 +102	+1%	+$5.38K	0.04%	329
2025 Q4	$384K	Buy	7,327 +382	+6%	+$22.9K	0.04%	308
2025 Q3	$450K	Sell	6,945 -400	-5%	-$23K	0.05%	282
2025 Q2	$357K	Buy	7,345 +996	+16%	+$38.5K	0.05%	301
2025 Q1	$216K	Buy	6,349 +1,182	+23%	+$50.1K	0.03%	362
2024 Q4	$203K	Buy	5,167 +803	+18%	+$37.9K	0.03%	391
2024 Q3	$205K	Buy	4,364 +663	+18%	+$33.6K	0.03%	408
2024 Q2	$210K	Buy	+3,701	New	+$214K	0.03%	395
2022 Q4	–	Sell	-3,073	Closed	-$201K	–	373
2022 Q3	$201K	Buy	+3,073	New	+$223K	0.06%	320

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

180 Wealth Advisors's CRSP Position: Q2 2026 in Review

180 Wealth Advisors reduced its CRISPR Therapeutics (CRSP) stake by 2.3% in Q2 2026, selling an estimated $9.07K and leaving 7,257 shares worth $396K. The position accounts for 0.04% of the portfolio, ranked #324.

180 Wealth Advisors first reported a position in CRSP in Q3 2022 and has held it in 10 quarters since. The position peaked at $450K in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

180 Wealth Advisors held 7,257 shares of CRISPR Therapeutics worth $396K as of Q2 2026.
180 Wealth Advisors sold 172 CRISPR Therapeutics shares in Q2 2026, an estimated $9.07K.
CRISPR Therapeutics made up 0.04% of 180 Wealth Advisors's portfolio in Q2 2026, its #324 holding.
180 Wealth Advisors first reported a position in CRISPR Therapeutics in Q3 2022 and has held it in 10 quarters since.
180 Wealth Advisors's CRISPR Therapeutics position peaked at $450K in Q3 2025.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on 180 Wealth Advisors's 13F filing for Q2 2026, filed 7 Jul 2026.